Liquid Biopsy and Challenge of Assay Heterogeneity for Minimal Residual Disease Assessment in Colon Cancer Treatment

Genes, Journal Year: 2025, Volume and Issue: 16(1), P. 71 - 71

Published: Jan. 9, 2025

This review provides a comprehensive overview of the evolving role minimal residual disease (MRD) for patients with Colon Cancer (CC). Currently, standard care non-metastatic CC is adjuvant chemotherapy (ACT) all stage III and high-risk II following surgical intervention. Despite 5-20% improvement in long-term survival outcomes, this approach also results significant proportion receiving ACT without any therapeutic benefit being unnecessarily exposed to risks secondary side effects. underscores an unmet clinical need more precise stratification distinguish who necessitate from those can be treated surgery alone. By employing liquid biopsy, it possible discern MRD enabling categorization as MRD-positive or MRD-negative, potentially revolutionizing management ACT. aimed examine heterogeneity methodologies currently available detection, encompassing state-of-the-art technologies, their respective advantages, limitations, technological challenges multi-omic approaches that utilized enhance assay performance. Furthermore, discussion was held regarding trials employ focusing on assays used. These differences methodology, target selection, performance risk producing inconsistent may not solely reflect biological/clinical but consequence preferential use particular products studies conducted different countries. Standardization harmonization will crucial ensure revolution delivers reliable clinically actionable outcomes patients.

Language: Английский

Contemporary Use of ctDNA for the Colorectal Surgeon

Clinics in Colon and Rectal Surgery, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 31, 2024

Abstract While advances in treatment and diagnostics have improved prognosis colorectal cancer (CRC), room for advancement remains, highlighting the importance of improving tools early detection guidance. Current national guidelines rely on stage-based recommendations but fail to identify patients with lower stage disease who a higher likelihood recurrence or those whom additional therapy may not be beneficial. Circulating tumor DNA (ctDNA) is an emerging noninvasive blood-based assay, which can inform status as single time point and/or longitudinal biomarker. ctDNA used diagnosis cancer, minimal/molecular residual disease, molecular profiling, assessing response. In operative management indicated, detectable associated worse survival outcomes. This review highlights expanding field CRC, underlining pivotal data areas need more research that are key surgeons understand.

Language: Английский